Core Focus: The Vision of Vaccine Autonomy On the afternoon of April 13, 2026, Minister of Health Dao Hong Lan met with the senior leadership delegation from Sanofi (France). The discussion centered on the technology transfer project for advanced vaccines to the Vietnam Vaccine Joint Stock Company (VNVC), a strategic step toward achieving self-sufficiency in high-quality vaccine supply within Vietnam.
Key Components of the Technology Transfer Project:
-
Advanced Vaccine Portfolio: The project prioritizes the transfer of technology for the 6-in-1 combination vaccine, seasonal flu vaccine, and meningococcal vaccine.
-
Domestic Production Capacity: While VNVC is accelerating the construction of its manufacturing facility, Sanofi committed to coordinating a team of top technical experts to provide direct support, ensuring compliance with rigorous global standards.
-
Strategic Benefits: Localizing production will enable Vietnam to proactively supply hundreds of millions of vaccine doses annually, reduce costs, and improve public access to world-class preventive healthcare products.
Institutional Reform and Investment Environment Minister Dao Hong Lan highlighted that the amended Law on Pharmacy (Law No. 44/2024/QH15) includes specific incentives for technology-transferred medications. The Ministry of Health pledged to continue administrative reforms, enhance management transparency, and resolve corporate challenges to create a favorable legal framework for multinational corporations like Sanofi to pursue long-term investment.
Commitment from Sanofi Sanofi representatives expressed their appreciation for Vietnam’s positive institutional changes in the healthcare sector. The corporation committed to partnering with the Ministry of Health to enhance disease prevention capabilities, strengthen the sustainability of the healthcare system, and maintain a people-centric approach in all development activities.